Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acetaminophen and atherosclerosis

This article was originally published in The Tan Sheet

Executive Summary

OTC analgesic inhibits an enzyme that can increase the unhealthy properties of low-density lipoproteins, Philip Greenspan, PhD, University of Georgia College of Pharmacy, reports at a conference co-sponsored by the American Heart Association and the North American Vascular Biology Organization in Denver May 21. The in vitro study - funded in part by Tylenol marketer McNeil Consumer Healthcare - aimed to examine the mechanism of effect acetaminophen has been shown to have on LDL and atherosclerosis (1"The Tan Sheet" Nov. 29, 1999, p. 24). The results suggest acetaminophen acts to inhibit myeloperoxidase, an enzyme associated with the disease-causing potential of LDL cholesterol. The study is being prepared for publication

You may also be interested in...


Clinically relevant doses of acetaminophen significantly decrease aortic fatty streak and total aortic area in hypercholesterolemic rabbits compared to placebo, Addison Taylor, MD/PhD, et al., Baylor College of Medicine, report in a study abstract presented at the American Heart Association annual meeting in Atlanta Nov. 10. The 12 rabbits, which received 100 mg/day acetaminophen through drinking water, also demonstrated significantly lower concentrations of five oxysterols in nmol/mg low density lipoprotein compared to 11 control rabbits. The rabbits all were fed a diet containing 1% cholesterol, with blood being collected

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts